Subscribe
Home
Issues
Issue Archive
Latest Issue
Special Issues
Browse By Topic
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In the News
Press Releases
Submit an Article
Author Guidelines
About
About RPM
Mission Statement
Contact Us
Categories
Oncology Practice Management - May 2015, Vol 5, No 4
340B Rules Remain in Flux
By
Rosemary Frei, MSc
Association of Community Cancer Centers
Rules surrounding implementation of 340B Drug Pricing, a government program that allows certain qualifying healthcare organizations to purchase reduced price outpatient medications, are in flux, according to a presentation at the recent Association of Community Cancer Centers 41st Annual Meeting in Arlington, VA.
Read More ›
The Nurse Practitioner’s Role in the Practice
By
Peggy Barton, RN, BSBA
Best Practices
Rewind about 5 years to 2010, and consider a few of the things that typically occurred in a medical practice: an infusion nurse sitting in the hall outside of an examination room, waiting for the physician to come out to answer a question about a patient.
Read More ›
SGR Repealed, But the Work Is Just Beginning
By
Gail Thompson
Payment Reform
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was signed into law on April 16, making history not just by repealing the sustainable growth rate (SGR) formula for Medicare physician payment, but for the resounding bipartisan support of the legislation after decades of partisan posturing in the US House of Representatives and Senate.
Read More ›
Federal Government Outlines Stage 3 of Meaningful Use
By
Rosemary Frei, MSc
Payment Reform
Criteria for Stage 3 of Meaningful Use was announced and published at the end of March, detailing benchmarks that eligible providers and hospitals will have to meet to qualify for certain incentive payments and avoid reimbursement penalties. The proposed ruling by the US Department of Health & Human Services and the Centers for Medicare & Medicaid Services (CMS) outlines a framework that is in some ways more flexible and in others more rigid than Stage 1 and Stage 2.
Read More ›
Waiting for the Carrot? It May Take a While
By
Dawn Holcombe, MBA, FACMPE, ACHE
From the Editor
The federal government is determined to shift Medicare’s traditional fee-for-service plans into alternative quality-based or value-based payment programs. Currently more than 400 accountable care organizations (ACOs) and more than 100 hospitals and other healthcare groups accept Medicare bundled payments, but they are predominantly focused on primary care.
Read More ›
FDA-Approved Medications Used for the Treatment of Leukemia
Drug Coding
This article assists healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of leukemia.
Read More ›
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
By
Lisa A. Raedler, PhD, RPh
Drug Updates
One of the most fear-inducing side effects of chemotherapy is nausea and vomiting. Without appropriate antiemetic prophylaxis, 70% to 80% of all patients with cancer who receive chemotherapy experience nausea and/or vomiting.
Read More ›
Trials Under Way for Patients with Melanoma
Clinical Trials Tracker
The following clinical trials are currently recruiting patients with melanoma for inclusion in several investigations.
Read More ›
Seven Steps to Finding the Right Financial Advisor
By
Lawrence B. Keller, CFP, CLU, ChFC, RHU, LUTCF
;
W. Ben Utley, CFP
Financial Management
As a physician with substantial income (or income potential), you will most likely be contacted by a number of individuals offering various types of financial products and services throughout your career. If you are in the market for an advisor, you will want to know the qualifications and experience level of each one you are considering.
Read More ›
Rest in Peace, SGR
By
Leah Ralph
ACCC: Patient and Provider Access
Recent months have brought unprecedented momentum on an issue physicians and Congress have been struggling with for more than a decade: repealing the sustainable growth rate (SGR) formula.
Read More ›
Page 1 of 2
1
2
December 2021, Vol 9, No 1
Read Now
Home
Issues
Issue Archive
Latest Issue
Special Issues
Browse By Topic
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In the News
Press Releases
Submit an Article
Author Guidelines
About
About RPM
Mission Statement
Contact Us